Purple Biotech (NASDAQ:PPBT) and Gemini Therapeutics (NASDAQ:GMTX) Financial Survey

Purple Biotech (NASDAQ:PPBT) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Profitability

This table compares Purple Biotech and Gemini Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-147.77%	-111.59%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Insider and Institutional Ownership

9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 3.0% of Purple Biotech shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Purple Biotech has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Purple Biotech and Gemini Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1	1	1	0	2.00
Gemini Therapeutics	0	0	0	0	0.00

Purple Biotech currently has a consensus target price of $30.00, indicating a potential upside of 1,634.10%. Given Purple Biotech’s stronger consensus rating and higher probable upside, equities analysts plainly believe Purple Biotech is more favorable than Gemini Therapeutics.

Earnings and Valuation

This table compares Purple Biotech and Gemini Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39 million	($23.25)	-0.07
Gemini Therapeutics	N/A	N/A	-$71.87 million	($1.00)	-82.41

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Purple Biotech beats Gemini Therapeutics on 6 of the 11 factors compared between the two stocks.

About Purple Biotech

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

About Gemini Therapeutics

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.